Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada (vol 25, pg 32, 2018)

被引：0
|
作者：
Chua, A.
Perrin, A.
Ricci, J. F.
Neary, M. P.
Thabane, M.
机构：
来源：
CURRENT ONCOLOGY | 2018年 / 25卷 / 04期
关键词：
D O I：
10.3747/co.25.4233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E354 / E355
页数：2
相关论文
共 50 条
  • [11] Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis (vol 24, pg 987, 2018)
    Vadagam, P.
    Kamal, K. M.
    Covvey, J. R.
    Giannetti, V
    Mukherjee, K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (02): : 285 - 286
  • [12] Cost-Effectiveness in Adult Spinal Deformity Surgery (vol 83, pg 597, 2018)
    Arutyunyan, Grigoriy G.
    NEUROSURGERY, 2019, 84 (03) : 815 - 815
  • [13] Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States.
    Casciano, Roman
    Chulikavit, Maruit
    Perrin, Allison
    Liu, Zhimei
    Wang, Xufang
    Babigumira, Joseph
    Garrison, Louis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [14] COST-EFFECTIVENESS OF IMATINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN PERSPECTIVE
    El Ouagari, K.
    Huse, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
  • [15] Cost-effectiveness (CE) of imatinib (IM) in the treatment of advanced gastrointestinal stromal tumors (GIST)
    Huse, Daniel
    Lenhart, Greg
    Feng, Weiwei
    Blanke, Charles
    Joensuu, Heikki
    Mehren, Margaret V.
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 162 - 162
  • [16] Cost-effectiveness analysis of abciximab: a Canadian hospital perspective (vol 32, pg 536, 1998)
    Zed, PJ
    Frighetto, L
    Sunderjin, R
    Marra, CA
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (7-8) : 845 - 845
  • [17] Identifying a missing lineage driver in a subset of lung neuroendocrine tumors (vol 32, pg 865, 2018)
    Pozo, Karine
    Minna, John D.
    Johnson, Jane E.
    GENES & DEVELOPMENT, 2018, 32 (17-18) : 1266 - 1266
  • [18] Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
    Yao, James C.
    Fazio, Nicola
    Singh, Simron
    Buzzoni, Roberto
    Carnaghi, Carlo
    Wolin, Edward
    Tomasek, Jiri
    Raderer, Markus
    Lahner, Harald
    Voi, Maurizio
    Pacaud, Lida Buboteishvili
    Rouyrre, Nicolas
    Sachs, Carolin
    Valle, Juan W.
    Delle Fave, Gianfranco
    Van Cutsem, Eric
    Tesselaar, Margot
    Shimada, Yasuhiro
    Oh, Do-Youn
    Strosberg, Jonathan
    Kulke, Matthew H.
    Pavel, Marianne E.
    LANCET, 2016, 387 (10022): : 968 - 977
  • [19] A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA
    Lakhdari, K.
    Young, K. C.
    Holdgate, O.
    Doan, J.
    VALUE IN HEALTH, 2018, 21 : S37 - S37
  • [20] COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
    Chen, W.
    Sheng, F.
    Qiao, N.
    VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
12345